Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy.
Conditions
Interventions
FM+R
Zevalin (Ibritumomab Tiuxetan)
Locations
1
Italy
Istituto di Ematologia e Oncologia Medica Seràgnoli
Bologna, BO, Italy
Last Updated
March 12, 2009
NCT06337318
NCT05006716
NCT06026319
NCT06510361
NCT07128641
NCT01804686
Lead Sponsor
University of Bologna
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions